| Basics |
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.
|
| IPO Date: |
June 1, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.64B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.44 | 2.69%
|
| Avg Daily Range (30 D): |
$0.47 | 2.58%
|
| Avg Daily Range (90 D): |
$0.37 | 2.10%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.2M |
| Avg Daily Volume (30 D): |
2.09M |
| Avg Daily Volume (90 D): |
1.55M |
| Trade Size |
| Avg Trade Size (Sh.): |
132 |
| Avg Trade Size (Sh.) (30 D): |
70 |
| Avg Trade Size (Sh.) (90 D): |
65 |
| Institutional Trades |
| Total Inst.Trades: |
9,623 |
| Avg Inst. Trade: |
$2.25M |
| Avg Inst. Trade (30 D): |
$3.35M |
| Avg Inst. Trade (90 D): |
$3.51M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.04M |
| Avg Closing Trade (30 D): |
$6.21M |
| Avg Closing Trade (90 D): |
$5.8M |
| Avg Closing Volume: |
168.17K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$.11
|
$.2
|
|
Diluted EPS
|
|
$.11
|
$.2
|
|
Revenue
|
$
|
$ 244.32M
|
$ 250.4M
|
|
Gross Profit
|
$
|
$ 223.93M
|
$ 231.54M
|
|
Net Income / Loss
|
$
|
$ 18.99M
|
$ 32.77M
|
|
Operating Income / Loss
|
$
|
$ 19.29M
|
$ 31.64M
|
|
Cost of Revenue
|
$
|
$ 20.39M
|
$ 18.86M
|
|
Net Cash Flow
|
$
|
$ -101.89M
|
$ -18.94M
|
|
PE Ratio
|
|
|
|
|
|
|
